AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01897142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for PF-05230907
Description: 3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
Study NCT01897142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: 5 micrograms per kilogram of PF-05230907, IV bolus, single dose
Study NCT01897142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for PF-05230907
Description: 5 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
Study NCT02301273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Physiotherapy
Description: o Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.
Study NCT02301273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Physiotherapy
Description: o Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
Study NCT03997149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute Laboratory Stressor
Description: The TSST was 20 minutes long and consisted of a five-minute instructional period where participants listened to a pre-recorded tape; a five-minute speech preparation period; a five-minute challenging serial subtraction task; and a five-minute videotaped public speaking task in front of a panel of three evaluative, non-affirming judges dressed in white coats.
Study NCT03997149 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low affect video
Description: The 20-minute TSST was replaced with a 20-minute low-affect educational film screening.
Study NCT01062282 — intervention group
Intervention type: DRUG
Intervention: Iloprost (Ventavis BAYQ6256)
Description: Patients with pulmonary arterial hypertension, classified as New York Heart Association functional class III or IV where the treating physician has chosen Ventavis as a suitable treatment prior to inclusion into this non-interventional study. Patients should not have received prior treatment with Ventavis
Study NCT03832582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Annexin
Description: All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
Study NCT03441841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine + Prilocaine
Description: Single topical dose of 2g lidocaine + prilocaine 2.5 % formulation.
Study NCT03441841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Single topical dose of 2g lidocaine 2.5 % formulation.
Study NCT03441841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine
Description: Single topical dose of 2g prilocaine 2.5 % formulation.
Study NCT02418507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Proprietary Probiotic Blend
Description: A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
Study NCT02418507 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is administered to randomized healthy participants
Study NCT03326973 — intervention group
Intervention type: BEHAVIORAL
Intervention: EuroQoL EQ-5D-3L
Description: Overall QOL
Study NCT03326973 — intervention group
Intervention type: BEHAVIORAL
Intervention: EORTC QLQ-C30
Description: General symptoms; physical, role, emotional, cognitive, and social functioning scales; fatigue, nausea/vomiting , and pain scales
Study NCT03326973 — intervention group
Intervention type: OTHER
Intervention: PRO-CTCAE
Description: Additional potential immune-specific symptoms
Study NCT03326973 — intervention group
Intervention type: BEHAVIORAL
Intervention: Fatigue severity score questionnaire
Description: Fatigue severity
Study NCT03326973 — intervention group
Intervention type: BEHAVIORAL
Intervention: The COST
Description: Financial toxicity; satisfaction with ability to work
Study NCT03326973 — intervention group
Intervention type: BEHAVIORAL
Intervention: Physician information
Description: Details on outside health providers
Study NCT02464345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAPIFED
Description: HAPIFED is adapted from CBT to promote a positive relationship with food, eating and activity, appetite awareness, and weight loss to be achieved over a longer and more intensive period of therapy, thus recognizing the importance of longer-term therapy in weight loss (Casazza et al., 2013). Notably, HAPIFED is also multidisciplinary. Clinical practice and consensus views are to utilize the special expertise of dietitians and other allied health professionals (Robinson, 2009).
Study NCT02464345 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-E
Description: CBT-E therapy
Study NCT01589445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone hydrochloride
Description: 77 patients were treated with pioglitazone hydrochloride (B001) for 3 months.Biomedical parameters were measured each month.
Study NCT01589445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride
Description: After the treatment with pioglitazone(001) for 3 months first and then patients were on one month washout period;in the washout period they were given metformin tablet 850mg once daily,then treated with 002 (metformin) for further 3 months. The same biomedical measurements were assayed.
Study NCT03890549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SnoreLab (smart phone application for snoring recording)
Description: The investigators selected 3 appropriate downloadable smart phone applications for snoring recording and make validation with the golden standard of polysomnography.
Study NCT03559179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Wizard
Description: The Opioid Wizard is an OUD clinical decision support tool for primary care providers.
Study NCT02562274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MP 1500 mg/day
Description: Subjects are received MP 1500 mg/day treatments once daily for 8 weeks
Study NCT03051568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Description: 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
Study NCT01450397 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: XIAFLEX
Description: One Injection of 0.58 mg of Xiaflex into the affected area of the hand.
Study NCT00614614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)
Description: One dose in the booster phase as intramuscular injection
Study NCT00043810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gelonin
Description: Gelonin-AntiCD33 purging, 3 purging concentrations (fixed dose of 5 x 10\^6 CD34+ cells/kg to be infused) with 3 dose levels of 1 nanomolar, 5.0 nanomolar and 10.0 nanomolar.
Study NCT00043810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 130 mg/m2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -6 to -3).
Study NCT00614614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)
Description: Three doses in the priming phase and, for Menhibrix 2 Group, one dose in the booster phase as intramuscular injection
Study NCT00614614 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix®
Description: One dose as intramuscular injection
Study NCT00283062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (TAXOTERE®) Chemotherapy
Description: 75 mg/m\^2 docetaxel administered IV over 1 hour on Day 1 q3w for 6 cycles. The first cycle was to be administered within 30 days after progression was confirmed.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy.
Study NCT00614614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix®
Description: One dose as intramuscular injection
Study NCT00614614 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB®
Description: Three doses in the priming phase as intramuscular injection
Study NCT00614614 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediarix®
Description: Three doses in the priming phase as intramuscular injection
Study NCT00614614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix®
Description: Three doses in the priming phase as intramuscular injection
Study NCT00911404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low CHO
Description: Diet with 40% total calories from carbohydrates. In the Low-CHO arm, 15% of calories from carbohydrates will be substituted by monounsaturated fat.
Study NCT00911404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High CHO diet
Description: Diet with 55% total calories from carbohydrates.
Study NCT04549688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high-intensity focused ultrasound, HIFU
Description: see above
Study NCT03063658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: The first dose of 1 gr intravenous paracetamol will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
Study NCT03063658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 800 mg
Description: The first dose of 800 mg intravenous ibuprofen will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
Study NCT01097018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m2 BID/ Days 1-14
Study NCT01097018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m2 BID/ Days 1-14
Study NCT01097018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perifosine
Description: 50 mg daily x 21 days
Study NCT01097018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill daily x 21 days
Study NCT00283062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate ( ELIGARD®) Hormonal Therapy
Description: 22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed (on Day 1 of docetaxel administration).
Study NCT00283062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate ( ELIGARD®) Hormonal Therapy
Description: 22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed.
Study NCT02063932 — intervention group
Intervention type: OTHER
Intervention: endomicroscopy, targeted biopsy and 16s rRNA gene sequencing
Study NCT04101188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Potassium/Low Sodium Diet
Description: Consumption of 10 days of a diet moderate in potassium and low in sodium.
Study NCT04101188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Potassium/High Sodium Diet
Description: Consumption of 10 days of a diet moderate in potassium and high in sodium.
Study NCT04101188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Potassium/High Sodium Diet
Description: Consumption of 10 days of a diet high in potassium and high in sodium.
Study NCT03731520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessing exercise behavior
Description: 11-point Numeric Analogue Scale (NRS) for satisfaction of exercising, Exercise Stages of Change Scale-Short Form (ESCS), Exercise Self-Efficacy Scale (ESES), and Decisional Balance Scale (DBS) for exercise behaviour will be inquired for the patients with JIA.
Study NCT04361981 — intervention group
Intervention type: OTHER
Intervention: Deep Venous Disease Diagnostic
Description: Clinical and/or echographic diagnosis of Deep Venous Disease in a patient with COVID-19 infection
Study NCT00668044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (BAYO9867)
Description: 400 mg iv BID
Study NCT00668044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (BAYO9867)
Description: 400 mg iv TID
Study NCT00862810 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Received HPV vaccine first
Study NCT00862810 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Received concomitant vaccines first
Study NCT02246673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 15 mg
Study NCT02246673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 10 mg
Study NCT02246673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 2.5
Study NCT02246673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 5 mg
Study NCT02246673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Study NCT02246673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Study NCT02937519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chrono-chemotherapy pump:Melodie
Study NCT02937519 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Routine intravenous drip
Study NCT02937519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction Chrono-chemotherapy
Study NCT02937519 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: induction Routine-chemotherapy
Study NCT02937519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin chrono-chemotherapy
Study NCT02937519 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin routine-chemotherapy
Study NCT02937519 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study NCT01420523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir-Maraviroc
Description: Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
Study NCT00690079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1386
Description: Oral admin. of doses at 11 days through a 12 days period. Cmax = 16 mikromol/L and AUCmax = 98 mikromol\*h/L
Study NCT00690079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral admin. of doses at 11 days through a 12 days period.
Study NCT04174430 — intervention group
Intervention type: BIOLOGICAL
Intervention: severe bronchiolitis
Description: Prematurity (gestational age ≤36 weeks), Low birth weight, Age less than 12 weeks,Chronic pulmonary disease, particularly bronchopulmonary dysplasia (also known as chronic lung disease), Anatomic defects of the airways, Hemodynamically significant congenital heart disease, Immunodeficiency, Neurologic disease
Study NCT01466556 — intervention group
Intervention type: OTHER
Intervention: Routine laboratory tests
Description: Laboratory tests to determine metabolic syndrome
Study NCT01745666 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise test
Description: Exercise test : Bruce protocol : exercise during 7 minutes, and rest during 6 minutes with registering of the electrocardiograms.
Study NCT02937519 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: intensity-modulated radiation therapy
Study NCT03888872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High tone power therapy
Description: 1- High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort. Duration: 60 min (Each one electrode to both thighs to the knee, each one electrode to both thighs to the groin). Position: lying / setting, Number of sessions: 10, Frequency of sessions: 3 times per week.
Study NCT03888872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected Physical Therapy Program
Description: Selected physical therapy program: (For both groups).~1. Wobble board training:~2. Active range of motion exercises (AROM):~3. Gentle manual stretching exercises for both UL \& LL:~4. Graduated gait training:
Study NCT01745666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise test
Description: Exercise test : Bruce protocol : exercise during 7 minutes, and rest during 6 minutes with registering of the electrocardiograms.
Study NCT04212221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGD013 monotherapy
Description: MGD013 monotherapy will start from Phase I dose escalation first, starting dose will be 120mg Q2W, the dose level may escalate sequentially following traditional 3+3 dose escalation scheme (120mg, 240mg, 400mg, 600mg) to determine the RP2D(recommended phase II dose) of MGD013 monotherapy. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 monotherapy with RP2D determined in Phase I study.
Study NCT04212221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGD013 in combination with Brivanib Alaninate
Description: After determining the RP2D of MGD013 monotherapy, MGD013 at the fixed dose will be combined with Brivanib Alaninate. Dose escalation study of the combination therapy in Phase I will adopt traditional 3+3 dose escalation scheme; the dosage of Brivanib will start from 200 mg QD, and may escalate to 400 mg QD, 600 mg QD and a maximum of 800 mg QD to to determine the RP2D of MGD013 in combination with Brivanib Alaninate. Then Phase II dose expansion study will initiate, patients will receive the fixed dose of MGD013 and Brivanib Alaninate combination therapy with RP2D determined in Phase I study.
Study NCT02996175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Sleep Treatment
Description: 1. Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems~2. Information on healthy sleep hygiene, preventative techniques, and use of visual supports~3. Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking~4. Information on procedures for delayed sleep onset and problematic sleep associations~5. Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future
Study NCT02996175 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care sleep treatment enhanced with psychoeducation
Description: 1. Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome~2. Introduction to understanding and interpreting results from clinical evaluations~3. Introduction to educational planning, expectations, and transition planning~4. Introduction to lifespan development and advocacy and support services available~5. Feedback on current concerns and methods for obtaining services to manage concerns
Study NCT00562081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: 24/7 access to a Certified Asthma Educator
Study NCT00562081 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: Patient does not have 24/7 access to a Certified Asthma Educator.
Study NCT01592773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride (HCl)
Description: During the 6-week double-blind dosing titration/maintenance period, Memantine extended-release 3-mg and 6-mg capsules; oral administration. Dosing was once daily.~During open-label treatment: Memantine extended-release 3mg capsules; oral administration. The maximum target dosage was identified during the prior studies for each patient. Dosing was once daily.
Study NCT00087594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)
Study NCT01745666 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Epinephrine test
Description: Epinephrine test : 1 hour after exercise test : epinephrine infusion during 20 minutes, and monitoring during 30 minutes after stop infusion with registering of electrocardiograms.
Study NCT01745666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epinephrine test
Description: Epinephrine test : 1 hour after exercise test : epinephrine infusion during 20 minutes, and monitoring during 30 minutes after stop infusion with registering of electrocardiograms.